Walleye Capital
BMRN icon

Walleye Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Walleye Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.87M Sell
33,100
-3,000
-8% -$175K 0.01% 1524
2025
Q4 		$2.15M Buy
36,100
+35,400
+5,057% +$1.93M 0.01% 1810
2025
Q3 		$37.9K Sell
700
-18,600
-96% -$1.06M ﹤0.01% 4095
2025
Q2 		$1.06M Sell
19,300
-10,600
-35% -$624K ﹤0.01% 2001
2025
Q1 		$2.11M Sell
29,900
-21,400
-42% -$1.44M 0.01% 1374
2024
Q4 		$3.37M Sell
51,300
-17,000
-25% -$1.14M 0.01% 1347
2024
Q3 		$4.8M Buy
68,300
+44,500
+187% +$3.72M 0.01% 1206
2024
Q2 		$1.96M Sell
23,800
-2,800
-11% -$233K ﹤0.01% 2125
2024
Q1 		$2.32M Buy
26,600
+21,500
+422% +$1.92M ﹤0.01% 1894
2023
Q4 		$492K Buy
5,100
+4,600
+920% +$407K ﹤0.01% 2961
2023
Q3 		$44.2K Sell
500
-700
-58% -$62.3K ﹤0.01% 4221
2023
Q2 		$104K Sell
1,200
-22,000
-95% -$2.07M ﹤0.01% 3416
2023
Q1 		$2.26M Buy
23,200
+17,700
+322% +$1.83M 0.03% 654
2022
Q4 		$569K Buy
+5,500
New +$516K 0.01% 1360
2020
Q1 		– Sell
-3,200
Closed -$271K – 967
2019
Q4 		$271K Sell
3,200
-17,900
-85% -$1.35M 0.02% 978
2019
Q3 		$1.42M Buy
21,100
+6,100
+41% +$470K 0.08% 324
2019
Q2 		$1.28M Sell
15,000
-2,900
-16% -$248K 0.14% 195
2019
Q1 		$1.59M Buy
+17,900
New +$1.66M 0.26% 67

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's BMRN Position: Q1 2026 in Review

Walleye Capital increased its BioMarin Pharmaceuticals (BMRN) stake by 64% in Q1 2026, buying an estimated $8.27M and bringing the position to 364,246 shares worth $20.6M. The position accounts for 0.09% of the portfolio, ranked #188.

Walleye Capital first reported a position in BMRN in Q1 2019 and has held it in 20 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Walleye Capital held 364,246 shares of BioMarin Pharmaceuticals worth $20.6M as of Q1 2026.
  • Walleye Capital bought 141,779 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $8.27M.
  • BioMarin Pharmaceuticals made up 0.09% of Walleye Capital's portfolio in Q1 2026, its #188 holding.
  • Walleye Capital first reported a position in BioMarin Pharmaceuticals in Q1 2019 and has held it in 20 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.